A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis
Clinical trial NCT03689829 · TERMINATED
Trial details
- NCT number
- NCT03689829
- Sponsor
- Lakefront Biotherapeutics NV
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-13
- Primary completion
- 2020-03-02
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.